Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
225Ac-ETN029 in Advanced DLL3-expressing Solid Tumors
NCT07006727Phase 1Recruiting
- Sponsor
- Novartis
- Start
- Oct 2025
- Primary completion
- Aug 2031
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of [225Ac]Ac-ETN029 in Small Cell Lung Cancer (SCLC), large cell neuroendocrine carcinoma of the lung (LCNEC), neuroendocrine prostate cancer (NEPC) and 8 more, sponsored by Novartis. Primary endpoints: Dose Limiting Toxicities at 6 weeks, Adverse Events and Serious Adverse Events up to 42 months and 2 more. Started Oct 2025; status: recruiting.
02
Drugs
[225Ac]Ac-ETN029
03
Conditions
Small Cell Lung Cancer (SCLC)large cell neuroendocrine carcinoma of the lung (LCNEC)neuroendocrine prostate cancer (NEPC)gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC)extrapulmonary neuroendocrine carcinoma (EPNEC)
Beyond the preview
Go deeper on NCT07006727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07006727.